JP2021527095A5 - - Google Patents

Info

Publication number
JP2021527095A5
JP2021527095A5 JP2020569143A JP2020569143A JP2021527095A5 JP 2021527095 A5 JP2021527095 A5 JP 2021527095A5 JP 2020569143 A JP2020569143 A JP 2020569143A JP 2020569143 A JP2020569143 A JP 2020569143A JP 2021527095 A5 JP2021527095 A5 JP 2021527095A5
Authority
JP
Japan
Prior art keywords
methyl
amino
dihydro
purine
methylquinoline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020569143A
Other languages
English (en)
Japanese (ja)
Other versions
JP7472044B2 (ja
JP2021527095A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2019/065686 external-priority patent/WO2019238929A1/en
Publication of JP2021527095A publication Critical patent/JP2021527095A/ja
Publication of JP2021527095A5 publication Critical patent/JP2021527095A5/ja
Application granted granted Critical
Publication of JP7472044B2 publication Critical patent/JP7472044B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020569143A 2018-06-15 2019-06-14 プリノン化合物及び癌の治療におけるそれらの使用 Active JP7472044B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862685325P 2018-06-15 2018-06-15
US62/685,325 2018-06-15
PCT/EP2019/065686 WO2019238929A1 (en) 2018-06-15 2019-06-14 Purinone compounds and their use in treating cancer

Publications (3)

Publication Number Publication Date
JP2021527095A JP2021527095A (ja) 2021-10-11
JP2021527095A5 true JP2021527095A5 (https=) 2022-06-23
JP7472044B2 JP7472044B2 (ja) 2024-04-22

Family

ID=67107385

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020569143A Active JP7472044B2 (ja) 2018-06-15 2019-06-14 プリノン化合物及び癌の治療におけるそれらの使用

Country Status (29)

Country Link
US (2) US11884671B2 (https=)
EP (1) EP3807278B1 (https=)
JP (1) JP7472044B2 (https=)
KR (1) KR102793666B1 (https=)
CN (1) CN112236431B (https=)
AR (1) AR114971A1 (https=)
AU (1) AU2019287295B2 (https=)
BR (1) BR112020025127A2 (https=)
CA (1) CA3102195A1 (https=)
CL (1) CL2020003131A1 (https=)
CO (1) CO2020015758A2 (https=)
CR (1) CR20200620A (https=)
DO (1) DOP2020000241A (https=)
EA (1) EA202190006A1 (https=)
EC (1) ECSP20080276A (https=)
ES (1) ES2931448T3 (https=)
IL (1) IL279370B2 (https=)
JO (1) JOP20200315B1 (https=)
MA (1) MA52886A (https=)
MX (1) MX2020013570A (https=)
NI (1) NI202000099A (https=)
PE (1) PE20210003A1 (https=)
PH (1) PH12020552148A1 (https=)
SG (1) SG11202012035WA (https=)
TW (1) TWI820146B (https=)
UA (1) UA126837C2 (https=)
UY (1) UY38263A (https=)
WO (1) WO2019238929A1 (https=)
ZA (1) ZA202100195B (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI899080B (zh) * 2019-05-27 2025-10-01 大陸商迪哲（江蘇）醫藥股份有限公司 Ｄｎａ依賴性蛋白激酶抑制劑
TWI807228B (zh) * 2019-11-25 2023-07-01 大陸商南京明德新藥研發有限公司 作為dna-pk抑制劑的嘧啶并吡咯類化合物
CN113121538B (zh) * 2019-12-31 2023-04-21 成都百裕制药股份有限公司 呋喃衍生物及其在医药上的应用
CN113121574B (zh) * 2019-12-31 2023-02-17 成都百裕制药股份有限公司 嘌呤衍生物及其在医药上的用途
WO2021136461A1 (zh) * 2019-12-31 2021-07-08 成都百裕制药股份有限公司 嘌呤衍生物及其在医药上的应用
TWI765640B (zh) * 2020-04-10 2022-05-21 大陸商南京明德新藥研發有限公司 作為dna-pk抑制劑的氨基嘧啶化合物及其衍生物
AU2021256235B2 (en) * 2020-04-17 2024-05-09 Kangbaida (Sichuan) Biotechnology Co., Ltd. Imidazolidinone derivatives and medical use thereof
WO2021260583A1 (en) 2020-06-24 2021-12-30 Astrazeneca Uk Limited Combination of antibody-drug conjugate and dna-pk inhibitor
WO2022017368A1 (zh) * 2020-07-20 2022-01-27 首药控股(北京)股份有限公司 Dna-pk选择性抑制剂及其制备方法和用途
AU2021346954A1 (en) * 2020-09-24 2023-05-25 Auckland Uniservices Limited Novel aminopyridines and their use in treating cancer
CN114573605A (zh) * 2020-12-01 2022-06-03 武汉光谷亚太医药研究院有限公司 Dna依赖蛋白激酶抑制剂及其应用
TW202241901A (zh) * 2020-12-21 2022-11-01 大陸商江蘇恆瑞醫藥股份有限公司 嘌呤酮衍生物、其製備方法及其在醫藥上的應用
CN114656486B (zh) * 2020-12-22 2023-09-19 江苏恒瑞医药股份有限公司 嘌呤酮类化合物、其制备方法及其在医药上的应用
CN114656487B (zh) * 2020-12-22 2023-11-14 江苏恒瑞医药股份有限公司 稠合嘧啶类化合物、其制备方法及其在医药上的应用
WO2022135555A1 (zh) * 2020-12-24 2022-06-30 江苏恒瑞医药股份有限公司 嘌呤酮类化合物、其制备方法及其在医药上的应用
CN116917288B (zh) * 2021-03-22 2026-04-14 成都赜灵生物医药科技股份有限公司 一种7,9-二氢嘌呤衍生物及其制药用途
CN117377676B (zh) * 2021-06-29 2026-04-07 康百达（四川）生物医药科技有限公司 嘌呤衍生物的晶型及其药物组合物
CN117940437A (zh) * 2021-09-07 2024-04-26 首药控股(北京)股份有限公司 Dna-pk选择性抑制剂及其制备方法和用途
WO2025199376A1 (en) * 2024-03-22 2025-09-25 Padarn Therapeutics, Inc. Cdk2 inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010002115A (es) * 2007-08-23 2010-06-01 Aztrazeneca Ab 2-anilinopurin-8-onas como inhibidores de ttk/mps1 para el tratamiento de trastornos .proliferativos.
US8591943B2 (en) * 2009-04-09 2013-11-26 Merck Sharp & Dohme Corp. Pyrazolo[1,5-a]pyrimidine derivatives as mTOR inhibitors
ES2629006T3 (es) * 2009-10-29 2017-08-07 Vectura Limited Derivados que contienen N-heteroarilo como inhibidores de la quinasa jak3
DE102010035744A1 (de) * 2010-08-28 2012-03-01 Merck Patent Gmbh Imidazolonylchinoline
SG10201601909TA (en) * 2011-03-11 2016-04-28 Gilead Calistoga Llc Combination Therapies For Hematologic Malignancies
EP2527344A1 (en) * 2011-05-25 2012-11-28 Almirall, S.A. Pyridin-2(1H)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases
JP6883653B2 (ja) * 2016-12-20 2021-06-09 アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ アミノ−トリアゾロピリジン化合物および癌の治療におけるその使用

Similar Documents

Publication Publication Date Title
JP2021527095A5 (https=)
US12291539B2 (en) KRAS G12C inhibitors
CN115103835B (zh) Il-17a调节剂及其用途
JP6893501B2 (ja) スルフィニルフェニル又はスルホンイミドイルフェニルベンザゼピン
CN111989332A (zh) 作为cdk抑制剂的大环化合物、其制备方法及其在医药上的应用
JP7592689B2 (ja) Ｓｔｉｎｇアゴニストとしての大環状化合物並びにその方法及び使用
CN111194318B (zh) 用于调节激酶的化合物固体形式
ES2925564T3 (es) Derivados de azetidina tal como moduladores de receptores de quimiocinas y usos de los mismos
US10745382B2 (en) Compounds useful as immunomodulators
ES2820827T3 (es) Formas sólidas de un compuesto modulador de quinasas
JP4739761B2 (ja) キナーゼ抑制物質としてのピロロ−ピラゾール置換誘導体
JP5878171B2 (ja) 抗ウイルス剤としてのピラゾロ［１，５−ａ］ピリミジン
WO2024138206A1 (en) Fluoropyridopyrimidine and fluoroquinazoline derivaties and methods of use thereof
ES3062441T3 (en) Antiviral compounds
JP6756435B2 (ja) Ｔｒａｉｌ誘導のためのファーマコフォア
JP2018527398A (ja) ヘテロ環式化合物およびそれらの使用
JP2017510595A5 (https=)
EA020703B1 (ru) Пиразолохиназолины
JP2005538099A5 (https=)
RU2016131189A (ru) ПРОИЗВОДНЫЕ ПИРРОЛО[3,2-d]ПИРИМИДИНА В КАЧЕСТВЕ ИНДУКТОРОВ ЧЕЛОВЕЧЕСКОГО ИНТЕРФЕРОНА
RU2022109286A (ru) Кристаллическая форма гидрата свободного основания лорлатиниба
CN111670183A (zh) 作为cdk8/19抑制剂的新型杂环化合物
JP4823894B2 (ja) 新規水溶性プロドラッグ
EP3590516B1 (en) Antitumor-effect enhancer using pyrazolo[3,4-d]pyrimidine compound
AU2018320419A1 (en) Morpholinylpyridone compounds